Table 1 Correlation between EILD and clinicopathological variables of the patients treated with eribulin

Age (years)

 Median (range)

56 (25 ~ 81 y)

57 (25–81 y)

52 (38–73 y)

0.37

PS

 0

104

34

70

0.05

 1

41

7

34

 2

12

1

11

Comorbid disease

 Yes

41

12

29

0.67

  Diabetes

7

4

3

  Hypertension

22

9

13

  Hyperlipidemia

6

1

5

  Others

14

2

12

 No

127

31

96

History of other malignancy

 Yes

4

0

4

0.57

 No

153

42

111

Breast surgery

 Yes

142

39

103

0.75

  Total mastectomy

101

25

76

  Breast-conserving surgery

35

13

22

  Bilateral surgery

6

1

5

 No

15

3

12

DFI (years)

 Median (range)

2.8 (0 ~ 26.5)

3.3 (0–15.6)

2.6 (0–26.5)

0.24

BMI

 Median (range)

22.2 (15.8 ~ 36.3)

24.5 (16.8 ~ 36.3)

21.5 (15.8 ~ 35.4)

<0.0001

HR (ER/PgR) status

 Negative

36

5

31

0.08

 Positive

121

37

84

HER2 status

 Negative

132

37

95

0.56

 Positive

25

5

20

Previous chemotherapy (including adjuvant setting)

 Anthracycline

  Yes

146

40

106

0.73

  No

11

2

9

 Taxane

  Yes

149

39

110

0.44

  No

8

2

5

 Capecitabine

  Yes

108

25

83

0.13

  No

49

17

32

Number of previous endocrine therapy for metastatic disease

 0

65

14

51

0.37

 1

34

14

20

 2

31

7

24

 3

18

4

14

 4

4

2

2

 5

4

1

3

 6

1

0

1

Type of prior treatment

 Chemotherapy

110

25

85

0.71

 Endocrine therapy

42

15

27

 No

5

2

3

Liver metastasis

 Yes

77

23

54

0.39

 No

80

19

61

Concurrent trastuzumab

 Yes

13

3

10

0.99

 No

144

39

105

Dose intensity of eribulin (mg/m2/week)

 Median (range)

0.72 (0.30 ~ 0.91)

0.72 (0.30–0.90)

0.72 (0.32–0.91)

0.76